New report calls for more research on women’s health issues
Jul 12, 2024
The National Academies of Sciences, Engineering and Medicine analysis noted that women are disproportionately affected by chronic illnesses, including Alzheimer’s disease, depression and osteoporosis.
FDA approves new drug to treat Alzheimer’s
Jul 02, 2024
In clinical trials, donanemab (Kisunla) modestly slowed the pace of thinking declines among patients in the early stages of the memory-robbing disease. But it also carried significant safety risks, including...
FDA advisers support new Alzheimer’s drug
Jun 11, 2024
A US Food and Drug Administration advisory panel voted unanimously on Monday to recommend that the benefits of a new drug for Alzheimer’s outweigh its harms, which can include brain swelling and...
More medical lab tests will soon face federal scrutiny, FDA says
Apr 29, 2024
Laboratory tests used by millions of Americans are soon to be classified as medical devices, and as such be regulated by the US Food and Drug Administration, the agency announced Monday.
Higher education may protect functioning with Alzheimer’s disease
Apr 03, 2024
The findings were seen among African American individuals, with greater protective effect in APOE ɛ4 noncarriers.
Nearly 7 million Americans have Alzheimer’s, and caregivers are stressed
Mar 20, 2024
Nearly 7 million American seniors are living with Alzheimer’s dementia, placing a huge strain on both personal caregivers and the US healthcare system, according to a new Alzheimer’s Association...
Gender life expectancy gap increased from 2010 to 2021
Nov 13, 2023
The leading contributors to the widening gender life expectancy gap from 2019 to 2021 included COVID-19 and unintentional injuries.
Higher, lower HDL cholesterol linked to increased risk for dementia
Oct 04, 2023
An increased risk for Alzheimer’s disease and related dementia was seen in association with higher and lower versus middle quintile of HDL-C.
Eligibility limited for anti-β amyloid mAbs in seniors with MCI
Aug 18, 2023
Few older adults with mild cognitive impairment or mild dementia were eligible for lecanemab or aducanumab after applying clinical trial criteria.
Excess Alzheimer’s, related dementia-linked mortality increased during COVID-19
Jul 19, 2023
Among nursing home/long-term care residents, pandemic-era ADRD-related excess deaths decreased from 34,259 in year 1 to 22,050 in year 2, but excess deaths at home remained high (34,487 and 28,804, respectively).